Test Price
1,400 AED✅ Home Collection Available
DMD/BMD Mutation Screening (26 Exons) – Prenatal in UAE | 1400 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
This prenatal genetic screening test detects deletions and duplications in 26 exons of the DMD gene with 99.9% diagnostic sensitivity using ISO‑certified methodology. Our service includes:
- Diagnostic Accuracy: Targeted multiplex PCR validated per international standards.
- Logistics: Hospital‑extraction only – no home phlebotomy for prenatal specimens.
- Post‑Test Counseling: Telephonic consultation with a consultant medical geneticist.
- Insurance Verification: Instant check via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This prenatal test screens for deletions and duplications in 26 exons of the DMD gene, enabling accurate prenatal diagnosis of Duchenne/Becker muscular dystrophy (DMD/BMD). The assay uses multiplex end‑point PCR technology, validated under ISO standards, to detect the most common genetic alterations associated with these X‑linked recessive disorders.
| Feature | Our Test (DNA Labs UAE) | Common Alternative |
|---|---|---|
| Methodology | Multiplex End‑Point PCR (Targeted 26‑exon screen) | MLPA or NGS (broader coverage but higher cost) |
| Turnaround Time | 4–5 business days | 7–14 days |
| Counseling Support | Post‑result telephonic guidance by a consultant medical geneticist | Not typically provided |
Physician Insight & Safety Protocols
"I emphasize that prenatal DMD/BMD test results must be interpreted in the context of full family history and clinical evaluation. Genetic counseling is essential for informed decision‑making. Our laboratory in Dubai Healthcare City provides this comprehensive support." — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration: 9294403
Advisory Notice
⚠️ Important Medication Advisory:
Do not discontinue any prescribed medication without consulting your physician. Sudden cessation of certain drugs may pose risks to maternal and fetal health.
Exclusion Criteria & Emergency Signs
- Insufficient or contaminated sample (requires recollection).
- Maternal cell contamination may affect result accuracy.
- After amniocentesis or CVS, seek emergency care for vaginal bleeding, severe cramps, or fluid leakage.
Patient FAQ & Clinical Guidance
1. When is prenatal DMD/BMD mutation screening recommended and what is its value?
Provides definitive prenatal detection of Duchenne/Becker muscular dystrophy by analyzing 26 DMD exons, enabling informed reproductive decisions. This test is indicated when there is a family history of DMD/BMD, known maternal carrier status, or clinical suspicion during pregnancy. Even without a family history, carrier screening may prompt this test. A “positive” result confirms the presence of a common deletion/duplication; “negative” rules out the tested mutations but does not exclude rare variants.
2. How is the sample collected and are there any risks?
Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. The sample is obtained via amniocentesis or chorionic villus sampling (CVS) performed by a specialist under ultrasound guidance. The complication rate is below 1% when performed by experienced hands. Alternatively, if a tissue specimen is required later, Secure Medical Courier Solid Tissue Specimen Retrieval can be arranged for archival testing.
3. How accurate is the result and what does a negative result indicate?
With 99.9% sensitivity for the targeted 26 exons, a negative result virtually rules out the most common DMD/BMD deletions and duplications. However, it does not exclude rare point mutations or deep intronic variants. If clinical suspicion persists, complete gene sequencing may be recommended. The test is performed in our ISO‑certified laboratory under strict quality controls.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and complies with all UAE federal laws, including:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensures patient data confidentiality.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governs health data processing.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – ensures clinical safety and patient consent.
Our laboratory is ISO 9001:2015 certified (Certificate: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | DMD/BMD Mutation Screening (26 Exons) – Prenatal |
| Price (AED) | 1,400 AED |
| Turnaround Time | 4–5 business days |
| Sample Type / Matrix | Amniotic fluid or chorionic villus sampling (Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.) |
| Methodology Used | Multiplex End‑Point PCR (26 Exon Panel) |
| ICD-10-CM Code | G71.0 |
| LOINC Code | 87762-1 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
For appointments & inquiries: +971 54 548 8731 | Hospital collection only. No home phlebotomy for prenatal specimens.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians